Cost-effectiveness analysis comparing “PARP inhibitors-for-all” to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer
Rafael I. González, Laura J. Havrilesky, Evan R. Myers, Angeles Alvarez Secord, Joseph Dottino, Andrew Berchuck, Haley Moss
Topics & Concepts
MedicineBiomarkerOncologyPARP inhibitorInternal medicineClinical trialCost effectivenessIntensive care medicineRisk analysis (engineering)Poly ADP ribose polymerasePolymeraseBiochemistryChemistryGenePARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentEconomic and Financial Impacts of Cancer